This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Rejuvant outperforms supplements in...
Tech scientific study publication

Rejuvant outperforms supplements in aging study

Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 29, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive results for Rejuvant in an independent study published in Cellular senescence are expected to significantly boost investor confidence in Ponce de Leon Health and the longevity supplement market. This could lead to increased sales and market share for Rejuvant, potentially impacting the stock prices of publicly traded companies in the nutraceutical and biotechnology sectors as investors seek similar opportunities.

Biotechnology Pharmaceuticals Nutraceuticals
Event Summary

Ponce de Leon Health announced the publication of a landmark peer-reviewed study in the scientific journal Cellular senescence. The independent study, which was not sponsored by Ponce de Leon Health, compared 84 commonly used supplements and drugs for their effect on biologic age in over 4,000 subjects. Rejuvant, a commercially available supplement from Ponce de Leon Health, was the only compound to achieve statistical significance, showing an average 1.8-year lower age residual. Other supplements, including standard CaAKG/AKG and NAD+ forms, were significantly less effective and statistically insignificant. Dr. Brian Kennedy (biogerontologist) and Dr. Nir Barzilai both provided positive endorsements for Rejuvant's effectiveness and plausible mechanism of action.

Entities Involved
priv
Ponce de Leon Health
Ponce de Leon Health highlighted the publication of an independent study showing its product, Rejuvant, significantly reduces biologic age, which is a positive development for the company's market position and product validation.
Importance 100.0 Sentiment 75.0
oth
Rejuvant
Rejuvant, a supplement produced by Ponce de Leon Health, was the only product in a study of 84 compounds to show a statistically significant reduction in biologic age, positioning it as a leading product in the longevity market.
Importance 100.0 Sentiment 80.0
per
Brian Kennedy (biogerontologist)
Brian Kennedy (biogerontologist), a senior author of the paper, endorsed Rejuvant's effectiveness in reducing biologic age, reinforcing the study's findings and the product's credibility.
Importance 70.0 Sentiment 30.0
per
Nir Barzilai
Nir Barzilai, President of the Academy of Geroscience, provided a positive assessment of Rejuvant, noting its plausible mechanism of action and supportive preclinical data, which further validates the product.
Importance 65.0 Sentiment 25.0
oth
Cellular senescence
Cellular senescence is the scientific journal that published the landmark peer-reviewed study, lending credibility to the findings.
Importance 60.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.